- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/3 | 1.22 | -46.39 | 1.52 | 4.99 | 22.26 | 4.99 | N/A | - | ||
| 2024/2 | 2.28 | 52.77 | 15.08 | 3.77 | 30.93 | 5.15 | N/A | - | ||
| 2024/1 | 1.49 | 8.51 | 65.8 | 1.49 | 65.8 | 5.37 | N/A | 主要係去年1月春節假期9天,實際工作天少;另逢1月流感季節，客戶對本公司產品需求大增，致合併營收較去年同期增加。 | ||
| 2023/12 | 1.38 | -44.97 | 5.44 | 18.82 | -21.54 | 5.29 | 1.02 | - | ||
| 2023/11 | 2.5 | 77.09 | 10.79 | 17.44 | -23.09 | 5.07 | 1.06 | - | ||
| 2023/10 | 1.41 | 22.03 | 26.39 | 14.94 | -26.84 | 5.01 | 1.07 | - | ||
| 2023/9 | 1.16 | -52.6 | -26.23 | 13.53 | -29.91 | 4.75 | 1.24 | - | ||
| 2023/8 | 2.44 | 112.36 | -29.36 | 12.38 | -30.24 | 4.85 | 1.22 | - | ||
| 2023/7 | 1.15 | -8.64 | -27.86 | 9.94 | -30.45 | 4.66 | 1.26 | - | ||
| 2023/6 | 1.26 | -44.18 | -48.17 | 8.79 | -30.78 | 4.7 | 1.21 | - | ||
| 2023/5 | 2.25 | 89.42 | -41.99 | 7.53 | -26.67 | 4.65 | 1.22 | - | ||
| 2023/4 | 1.19 | -1.18 | -35.22 | 5.27 | -17.34 | 4.37 | 1.3 | - | ||
| 2023/3 | 1.2 | -39.23 | -14.13 | 4.09 | -10.12 | 4.09 | 1.44 | - | ||
| 2023/2 | 1.98 | 120.1 | 1.76 | 2.88 | -8.33 | 4.19 | 1.41 | - | ||
| 2023/1 | 0.9 | -30.98 | -24.77 | 0.9 | -24.77 | 4.46 | 1.32 | - | ||
| 2022/12 | 1.3 | -42.18 | -6.56 | 23.99 | 26.16 | 4.68 | 1.17 | - | ||
| 2022/11 | 2.26 | 102.02 | 7.44 | 22.68 | 28.75 | 4.94 | 1.11 | - | ||
| 2022/10 | 1.12 | -28.77 | -2.88 | 20.43 | 31.64 | 6.14 | 0.89 | - | ||
| 2022/9 | 1.57 | -54.61 | 11.33 | 19.31 | 34.4 | 6.62 | 0.81 | - | ||
| 2022/8 | 3.45 | 116.88 | 58.77 | 17.74 | 36.91 | 7.47 | 0.71 | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/7 | 1.59 | -34.36 | -6.81 | 14.29 | 32.5 | 7.9 | 0.68 | - | ||
| 2022/6 | 2.43 | -37.52 | 35.11 | 12.69 | 39.91 | 8.15 | 0.68 | - | ||
| 2022/5 | 3.88 | 111.51 | 52.78 | 10.27 | 41.09 | 7.12 | 0.78 | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/4 | 1.84 | 30.98 | 84.86 | 6.38 | 34.81 | 5.19 | 1.08 | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/3 | 1.4 | -27.98 | 26.68 | 4.55 | 21.52 | 4.55 | 1.19 | - | ||
| 2022/2 | 1.95 | 62.69 | 15.26 | 3.14 | 19.35 | 4.54 | 1.19 | - | ||
| 2022/1 | 1.2 | -14.27 | 26.67 | 1.2 | 26.67 | 4.69 | 1.16 | - | ||
| 2021/12 | 1.4 | -33.52 | -18.89 | 19.01 | 21.2 | 4.65 | 1.14 | - | ||
| 2021/11 | 2.1 | 82.6 | -1.85 | 17.62 | 26.14 | 4.66 | 1.14 | - | ||
| 2021/10 | 1.15 | -18.34 | -0.1 | 15.52 | 31.2 | 4.73 | 1.12 | - | ||
| 2021/9 | 1.41 | -35.27 | 9.04 | 14.37 | 34.58 | 5.29 | 1.08 | - | ||
| 2021/8 | 2.18 | 27.29 | 31.07 | 12.96 | 38.1 | 5.68 | 1.01 | - | ||
| 2021/7 | 1.71 | -4.83 | 66.01 | 10.78 | 39.61 | 6.05 | 0.94 | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，及新併入之子公司營收，致整體營收增加。 | ||
| 2021/6 | 1.8 | -29.34 | 125.5 | 9.07 | 35.54 | 5.33 | 1.09 | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，致整體營收增加。 | ||
| 2021/5 | 2.54 | 155.92 | 67.32 | 7.28 | 23.39 | 4.64 | 1.25 | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，致整體營收增加。 | ||
| 2021/4 | 0.99 | -10.24 | 2.3 | 4.73 | 8.15 | 3.79 | 1.53 | - | ||
| 2021/3 | 1.11 | -34.46 | 14.17 | 3.74 | 9.81 | 3.74 | 1.57 | - | ||
| 2021/2 | 1.69 | 78.79 | 3.2 | 2.63 | 8.08 | 4.35 | 1.35 | - | ||
| 2021/1 | 0.94 | -45.11 | 18.07 | 0.94 | 18.07 | 4.81 | 1.23 | - | ||
| 2020/12 | 1.72 | -19.55 | 6.61 | 15.69 | -0.33 | 5.01 | 1.12 | - | ||
| 2020/11 | 2.14 | 85.85 | 8.69 | 13.97 | -1.13 | 4.58 | 1.22 | - | ||
| 2020/10 | 1.15 | -10.87 | 7.98 | 11.83 | -2.72 | 4.1 | 1.37 | - | ||
| 2020/9 | 1.29 | -22.19 | 25.46 | 10.67 | -3.75 | 3.98 | 1.1 | - | ||
| 2020/8 | 1.66 | 61.22 | 1.11 | 9.38 | -6.74 | 3.49 | 1.26 | - | ||
| 2020/7 | 1.03 | 29.26 | 23.06 | 7.72 | -8.27 | 3.35 | 1.31 | - | ||
| 2020/6 | 0.8 | -47.57 | -14.87 | 6.69 | -11.73 | 3.29 | 1.22 | - | ||
| 2020/5 | 1.52 | 56.47 | -8.82 | 5.9 | -11.28 | 3.46 | 1.16 | - | ||
| 2020/4 | 0.97 | 0.17 | -30.94 | 4.38 | -12.11 | 3.58 | 1.12 | - | ||
| 2020/3 | 0.97 | -40.76 | -9.42 | 3.41 | -4.7 | 3.41 | 1.08 | - | ||
| 2020/2 | 1.64 | 104.56 | 14.17 | 2.44 | -2.68 | 4.05 | 0.91 | - | ||
| 2020/1 | 0.8 | -50.44 | -25.27 | 0.8 | -25.27 | 4.38 | 0.84 | - | ||
| 2019/12 | 1.61 | -17.98 | 24.36 | 15.74 | 11.81 | 4.65 | 0.77 | - | ||
| 2019/11 | 1.97 | 84.63 | 8.49 | 14.13 | 10.53 | 4.06 | 0.88 | - | ||
| 2019/10 | 1.07 | 3.55 | -30.5 | 12.16 | 10.87 | 3.74 | 0.96 | - | ||
| 2019/9 | 1.03 | -37.29 | 29.25 | 11.09 | 17.6 | 3.51 | 0.98 | - | ||
| 2019/8 | 1.64 | 96.22 | 2.35 | 10.06 | 16.53 | 3.41 | 1.01 | - | ||
| 2019/7 | 0.84 | -10.58 | -8.08 | 8.42 | 19.77 | 3.44 | 1.0 | - | ||
| 2019/6 | 0.94 | -43.85 | -27.47 | 7.58 | 23.91 | 4.01 | 0.82 | - | ||
| 2019/5 | 1.67 | 18.52 | 15.85 | 6.65 | 37.64 | 0.0 | N/A | - | ||
| 2019/4 | 1.41 | 31.38 | 84.38 | 4.98 | 46.89 | 0.0 | N/A | 主係認列香港威高寶齡第二期里程金和台灣寶齡醫療及消費通路及珠海寶展電商通路銷售成長所致 |
| 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
|---|---|---|---|---|---|---|---|---|---|
| 2024/1 | 1.49 | 2023/1 | 0.9 | 2022/1 | 1.2 | 2021/1 | 0.94 | 2020/1 | 0.8 |
| 2024/2 | 2.28 | 2023/2 | 1.98 | 2022/2 | 1.95 | 2021/2 | 1.69 | 2020/2 | 1.64 |
| 2024/3 | 1.22 | 2023/3 | 1.2 | 2022/3 | 1.4 | 2021/3 | 1.11 | 2020/3 | 0.97 |
| N/A | N/A | 2023/4 | 1.19 | 2022/4 | 1.84 | 2021/4 | 0.99 | 2020/4 | 0.97 |
| N/A | N/A | 2023/5 | 2.25 | 2022/5 | 3.88 | 2021/5 | 2.54 | 2020/5 | 1.52 |
| N/A | N/A | 2023/6 | 1.26 | 2022/6 | 2.43 | 2021/6 | 1.8 | 2020/6 | 0.8 |
| N/A | N/A | 2023/7 | 1.15 | 2022/7 | 1.59 | 2021/7 | 1.71 | 2020/7 | 1.03 |
| N/A | N/A | 2023/8 | 2.44 | 2022/8 | 3.45 | 2021/8 | 2.18 | 2020/8 | 1.66 |
| N/A | N/A | 2023/9 | 1.16 | 2022/9 | 1.57 | 2021/9 | 1.41 | 2020/9 | 1.29 |
| N/A | N/A | 2023/10 | 1.41 | 2022/10 | 1.12 | 2021/10 | 1.15 | 2020/10 | 1.15 |
| N/A | N/A | 2023/11 | 2.5 | 2022/11 | 2.26 | 2021/11 | 2.1 | 2020/11 | 2.14 |
| N/A | N/A | 2023/12 | 1.38 | 2022/12 | 1.3 | 2021/12 | 1.4 | 2020/12 | 1.72 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
